Choosing a drug development partner in 2026: A practical selection framework

As pipelines across modalities diversify, regulatory scrutiny intensifies, and the margin for error in development execution continues to shrink, partnering with a CDMO has never been more critical. As pipelines across modalities diversify, regulatory scrutiny intensifies, and the margin for error in development execution continues to shrink, partnering with a CDMO has never been more critical. For emerging and mid-sized biopharma companies, selecting a drug development partner is now a strategic decision that can determine whether a programme advances efficiently or becomes mired in avoidable delays. With increasingly complex clinical trials and stringent regulatory environments to contend with, some of…

Source: Clinical Trials Arena